Projects

Head of Department
RNDr. Michal Dubovický, CSc.

National

Current
  • Neuroprotective and cardioprotective potential of phenol acids in the prevention of civilization diseases
    Program: VEGA
    Duration: 1. 1. 2023 – 31. 12. 2026
  • Novel antidepressant therapy - long term consequencies on offspring
    Program: SRDA
    Duration: 1. 7. 2020 – 28. 6. 2024
  • -
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
  • Prenatal programming of adult diseases: treatment and prevention of outcomes of gestational hypoxia in rat offspring
    Program: VEGA
    Duration: 1. 1. 2020 – 31. 12. 2023
Finished
  • -
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • -
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Prenatal and postnatal effects of δ and µ opioid receptor ligands on the hippocampal development and function
    Program: SRDA
    Duration: 1. 7. 2016 – 30. 6. 2020
  • Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin
    Program: VEGA
    Duration: 1. 1. 2016 – 31. 12. 2019
  • Mechanisms, early detection and therapy of asphyxial injury in perinatal period - comparison of experimental data with clinical observation of asphyxial newborns
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Study of consequences of maternal depression and antidepressant venlafaxine treatment on functional development of the brain and behavior of rat offspring
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • -
    Program:
    Duration: 1. 9. 2015 – 31. 8. 2018
  • Prenatal programming of psychiatric diseases: experimental approaches for evaluation of causes and mechanisms of their origin
    Program: VEGA
    Duration: 1. 1. 2012 – 31. 12. 2015
  • The study of mechanisms and possible early detection of embryofetal damage caused by intrauterine perinatal hypoxia
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 10. 2014
  • -
    Program: VEGA
    Duration: 1. 1. 2011 – 31. 10. 2014
  • Early screening of anxiolytic and antidepressive properties of pyridoindole derivatives
    Program: VEGA
    Duration: 1. 1. 2009 – 31. 12. 2011
  • Experimental models of perinatal asphyxia in evaluation of behavioral disorders and possibility of pharmacological intervention
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Developmental Origin of Metabolic Syndrome:Hypertension, Diabetes and Dyslipidemia
    Program: VEGA
    Duration: 1. 1. 2008 – 31. 12. 2010
  • Long-term administration of low dose of L-NAME: Possibility to improve function of vessel wall in border hypertension?
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Long-term low dose L-NAME treatment:Possibility to improve the vascular function in borderline hypertension?
    Program: VEGA
    Duration: 1. 1. 2007 – 31. 12. 2009
  • Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
    Program: SRDA
    Duration: 1. 9. 2006 – 31. 10. 2009
  • Contribution to prevention and treatment of behavioural disorders evoked by hypotic-ischaemic damage of the brain in perinatal period: experimental model of asphyxia and administration of substances with antiradical and antioxidative effects
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • Study of neuroprotective action of new pyridoindole antioxidants
    Program: VEGA
    Duration: 1. 1. 2005 – 1. 12. 2007
  • The interaction of stress and genetic factors in the etiology of high blood pressure and behavioral failure: the role of nitric oxide
    Program: VEGA
    Duration: 1. 1. 2004 – 31. 12. 2006